Corporate ActionApr 29, 2026, 04:55 PM
SNTI Completes Holding Company Reorganization; Amends 10-K Part III
AI Summary
Senti Biosciences, Inc. completed a holding company reorganization on April 24, 2026, making the Company the successor registrant to Former Senti. This Amendment No. 1 to the Form 10-K updates and restates Items 10 through 14 of Part III, covering directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees. New certifications from the CEO and CFO are filed as exhibits.
Key Highlights
- Holding company reorganization completed on April 24, 2026.
- Company became successor registrant to Former Senti.
- Amendment No. 1 updates Items 10-14 of Part III of 10-K.
- Non-employee director annual retainer: $35,000.
- Audit Committee Chairperson annual retainer: $15,000.
- Compensation Committee Chairperson annual retainer: $15,000.
- Nominating & Corporate Governance Committee Chairperson annual retainer: $8,000.
- Initial stock option award for new directors: 43,900 shares.
Price Impact
More from SNTI